A new weight loss drug tested in a large international clinical trial produced an average body weight reduction of 16.6 percent, roughly equivalent to 39.2 pounds, in adults living with obesity or overweight who did not have type 2 diabetes. The results were announced by Boehringer Ingelheim, a biopharmaceutical company headquartered in Ingelheim, Germany, following the conclusion of its Phase 3 SYNCHRONIZE-1 trial in April 2026.
The trial ran for 76 weeks and enrolled 725 adults at multiple international sites. Participants received weekly injections of survodutide at doses of either 3.6 milligrams or 6.0 milligrams, or a placebo. Those in the placebo group lost an average of just 3.2 percent of their body weight over the same period.
The gap between the two groups was wide on a second measure as well. Up to 85.1 percent of participants treated with survodutide achieved at least a 5 percent reduction in body weight from their starting point, compared with only 38.8 percent of those who received the placebo.
Survodutide works differently from several other weight loss drugs already on the market. While it activates GLP-1 receptors, the same mechanism used by drugs like semaglutide, it also activates glucagon receptors. That second action is believed to regulate metabolic functions in the liver, which may produce additional reductions in liver fat and potentially reduce liver inflammation and fibrosis, two complications associated with obesity.
That dual mechanism sets it apart from tirzepatide, the active ingredient in Mounjaro and Zepbound, which also combines two receptor targets but pairs GLP-1 with glucose-dependent insulinotropic polypeptide, or GIP, receptors rather than glucagon receptors. The distinction matters because it may give survodutide particular value in treating metabolic dysfunction-associated steatohepatitis, known as MASH, a liver condition linked to obesity.
In addition to weight loss, participants treated with survodutide showed reductions in waist circumference, which researchers described as a key predictor of cardiometabolic risk. Those metabolic improvements suggest the drug may address not just body weight but a broader range of obesity-related health concerns.
Survodutide has not yet been approved for use by any regulatory body. Boehringer Ingelheim has not announced a timeline for a regulatory submission, though the company described the SYNCHRONIZE-1 results as promising. Additional trials, including studies involving patients with type 2 diabetes and those with MASH, are expected to help shape the drug's path toward potential approval.